Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis.  The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and  operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone.  The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and  a proprietary data analytics platform powering a new holistic approach to dialysis care.  

SLR Capital Partners

Baxter Ventures

Warburg Pincus

T. Rowe Price

Partner Fund Management

Perceptive Advisors

Fidelity Management and Research Company

D1 Capital Partners

Fidelity

Every time #TeamOutsetMedical gets together, we find ways to connect with each other, our communities and the causes we care about. At our National Sales Meeting last week, the team took time to give back to a cause close to so many of our hearts — empowering and supporting U.S. military servicemembers and their families.

As part of #operationlegacy with the Travis Manion Foundation, we assembled 1,000 care packages for donation to the Fort Campbell USO. The care packages were filled with gratitude, love, and essential items, our way of making a meaningful impact on the lives of those serving our nation and their loved ones. #BetterBeginsNow

#IfNotMeThenWho #TeamBuilding #MilitarySupport #VeteransSupport #CommunityService #ThankYouVeterans

NYU Langone Health Hospital — Long Island's #TabloDialysis program is empowering both patients and staff alike with remote monitoring, an innovative care model, and greater patient autonomy. Introducing Tablo "was a game changer," says FAITH LYNCH, DNP, RN, CNN, director of acute and home dialysis services. 

Read more about how NYU Langone Hospital is leading the way in dialysis care innovation: 

Switching to home hemodialysis can be game-changing. David Rush, a recording artist and patient advocate, gained back precious time. Terry, in rural Illinois, now enjoys treatments around his lifestyle, not tedious commutes. Regina, always active and vibrant, found empowerment being proactive and accountable in her care.

See how #Tablodialysis has made a profound impact on each of their lives. 

#BetterBeginsNow


Our Chair & CEO Leslie Trigg and CFO Nabeel Ahmed spoke this week at the 42nd Annual J.P. Morgan Healthcare Conference, where they highlighted the difference we strive to make in the lives of patients -- our moral mission -- as well as our growth as a company over the past year. We shared our progress serving acute care providers, with #TabloDialysis systems now in use at more than 650 facilities, including the top 8 national health systems and top 10 subacute providers, bolstered by a 34% increase in the number of Tablo consoles placed across home and acute care settings in 2023. #BetterBeginsNow #JPMHC24

It's like Coach Ted Lasso said, sometimes you've just gotta "believe."

#BetterBeginsNow #TeamTablo #TabloDialysis #NewYearVibes

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	2.01M -	15.08M 651.27%	49.94M 231.18%	102.60M 105.47%	115.38M 12.45%	130.38M 13.00%
cost of revenue	8.12M -	32.88M 304.83%	62.97M 91.52%	94.99M 50.85%	97.54M 2.68%	101.38M 3.93%
gross profit	-6.12M -	-17.80M 191.12%	-13.04M 26.77%	7.61M 158.36%	17.83M 134.40%	29M 62.62%
selling and marketing expenses	11.28M -	20.26M 79.62%	45.07M 122.46%	65.07M 44.38%	89.48M 37.52%	96.23M 7.54%
general and administrative expenses	6.25M -	8.92M 42.64%	30.51M 242.10%	36.32M 19.02%	40.52M 11.56%	45.23M 11.64%
selling general and administrative expenses	17.53M -	29.18M 66.43%	75.58M 159.03%	101.39M 34.14%	130.00M 28.22%	141.46M 8.82%
research and development expenses	22.92M -	23.33M 1.79%	28.85M 23.68%	36.74M 27.35%	48.85M 32.97%	57.31M 17.30%
other expenses
cost and expenses	48.57M -	85.39M 75.80%	167.40M 96.06%	233.12M 39.26%	276.39M 18.56%	300.15M 8.59%
operating expenses	40.45M -	52.51M 29.81%	104.43M 98.90%	138.13M 32.27%	178.85M 29.48%	198.77M 11.14%
interest expense	4.64M -	4.26M 8.23%	2.37M 44.44%	1.72M 27.48%	3.57M 107.93%	12.68M 255.44%
ebitda	-43.78M -	-65.89M 50.48%	-117.47M 78.29%	-130.02M 10.69%	-157.73M 21.31%	-153.79M 2.50%
operating income	-46.56M -	-70.31M 50.99%	-117.47M 67.08%	-130.52M 11.11%	-161.02M 23.37%	-169.77M 5.43%
depreciation and amortization	1.07M -	4.42M 313.47%	3.16M 28.53%	498K 84.24%	3.29M 560.84%	5.81M 76.54%
total other income expenses net	-262K -	2.03M 874.05%	-4.03M 298.47%	-1.22M 69.76%	-1.64M 34.92%	-2.50M 52.50%
income before tax	-49.76M -	-68.28M 37.23%	-121.49M 77.93%	-131.74M 8.43%	-162.66M 23.47%	-172.27M 5.91%
income tax expense	25K -	20K 20%	-794K 4,070.00%	199K 125.06%	295K 48.24%	523K 77.29%
net income	-49.78M -	-68.30M 37.20%	-120.70M 76.72%	-131.94M 9.31%	-162.96M 23.51%	-172.80M 6.04%
weighted average shs out	30.08M -	42.33M 40.71%	42.72M 0.93%	45.59M 6.71%	48.16M 5.64%	49.59M 2.96%
weighted average shs out dil	30.08M -	42.33M 40.71%	42.72M 0.93%	45.59M 6.71%	48.16M 5.64%	49.59M 2.96%
eps	-1.65 -	-1.61 2.42%	-2.83 75.78%	-2.89 2.12%	-3.38 16.96%	-3.48 2.96%
epsdiluted	-1.65 -	-1.61 2.42%	-2.83 75.78%	-2.89 2.12%	-3.38 16.96%	-3.48 2.96%

NASDAQ:OM

Outset Medical, Inc.

Last Close

3.71

26/07 20:00

Market Cap

205.86M

Beta: 1.48

Volume Today

347.66K

Avg: 593.47K

PE Ratio

−0.89

PFCF: −1.08

Preview